Gilead Sciences
India  /  Published 12.04.21

Ban on export of remdesivir

By G.S. Mudur in New Delhi

Calcutta  /  Published 01.04.21

$8-million connect with city

Liver Foundation then planned to build John C. Martin Center for Liver Research and Innovations. “He asked me why we were naming it after him. I said he was a great scientist and philanthropist ...
By Sanjay Mandal in Calcutta

India  /  Published 22.11.20

Covid-19: India set to stick with remdesivir

Eligible coronavirus disease patients will continue to receive the antiviral drug remdesivir even though the World Health Organisation has recommended against its use in hospitalised patients, top med...
By G.S. Mudur in New Delhi

Health  /  Published 29.04.20

Chinese study damper on drug

The first randomised clinical trial of the anti-viral medication remdesivir in patients with the novel coronavirus disease (Covid-19) has failed to find significant clinical benefits, Chinese doctors ...
By G.S. Mudur in New Delhi

West Bengal  /  Published 09.12.18

Pharma boss’s $8 million for Calcutta hospital

By Rith Basu in Sonarpur

Business  /  Published 07.06.20

AstraZeneca seeks merger with Gilead

Britain’s AstraZeneca Plc has approached US rival Gilead Sciences Inc about a possible merger that would form one the world’s largest drug companies, Bloomberg News reported on Sunday, citing peop...
By Reuters in London

India  /  Published 13.05.20

Candidate drug deal with India, Pak firms

US company Gilead Sciences announced on Wednesday it had signed pacts with five generic drug makers in India and Pakistan to expand the supply of remdesivir, a candidate drug for the treatment of Covi...
By G.S. Mudur in New Delhi

India  /  Published 28.06.19

Drug price promise ‘falter’

The US-based pharmaceutical company Gilead Sciences has not kept its September 2018 promise to lower prices of a drug to treat brain infections in patients with advanced HIV infections, the humanitari...
By Our Special Correspondent in New Delhi


Download our latest App

to get update on the go...

Copyright © 2020 The Telegraph. All rights reserved.